Octapharma AG

ALBUNORM

Pharmaceutical products, in particular blood plasma products, in particular proteins or protein solutions;

ATENATIV

Pharmaceutical preparations, namely, antithrombotic agent;

ATENATIV

Pharmaceutical preparations, namely, antithrombotic agent;

ATENATIV

Pharmaceutical preparations, namely, antithrombotic agent;

AXARA

Pharmaceutical preparations, namely preparations containing immunoglobulins; immunoglobulins for injection;

BALFAXAR

Pharmaceutical products, namely, blood plasma derived products, namely, prothrombin;

BALFAXAR

Pharmaceutical products, namely, blood plasma derived products, especially prothrombin for the treatment or prevention of blood or bleeding disorders;

CUTAQUIG

Pharmaceutical products, in particular medicines containing immunoglobulins extracted from blood plasma for injections;The wording CUTAQUIG has no meaning in a foreign language.;

DREAM...DO...GROW!

Pharmaceuticals and pharmaceutical preparations for treating emergency and trauma conditions, bleeding disorders, and immunological disorders; Pharmaceutical preparations, namely, blood plasma, blood plasma derivatives, blood plasma coagulation factors in the nature of Factor VIII and Von Willebrand factor blood-clotting proteins, blood plasma proteins in the nature of immunoglobulins, recombinant blood plasma derivatives, recombinant blood plasma factors, recombinant blood plasma proteins and recombinant immunoglobulins, all for treating emergency and trauma conditions, bleeding disorders, and immunological disorders;Public relations services;Medical services, namely, medical services provided at a blood donation center, medical consultancy services and health care consultancy services especially for people with bleeding disorders; medical information services, especially for people with bleeding disorders; medical consultancy services especially for people with bleeding disorders;

DREMSIS

Pharmaceutical products, namely, blood plasma preparations;

EMFAKTA

Pharmaceutical products, namely, blood plasma derived products, especially prothrombin;

EMGLOVI

Pharmaceutical products, in particular medicines containing immunoglobulins extracted from blood plasma for injections;The wording EMGLOVI has no meaning in a foreign language.;

FACTOR MY WAY

Advertising and business services;

FIBREMA

Pharmaceutical products, namely, blood-clotting factor, in particular fibrinogen;

FIBROCTA

Pharmaceutical products, namely, blood-clutting factor, in particular fibrinogen;

FIBRYGA

Pharmaceutical preparations, namely, blood clotting factors, in particular fibrinogen;

GLOBIGA

Pharmaceutical products, namely, products derived from blood plasma, particularly immunoglobulin;

INOVIQ

Pharmaceutical products, namely, blood plasma clotting factors, particularly recombinant factor VIII;

JUVENOCT

Pharmaceutical products, namely blood coagulation factors, particularly recombinant factors VIII;

LYOPLASLG

Pharmaceutical products, namely, blood plasma preparations;

MYCUTAQUIG

MY CUTAQUIG;Marketing services; product and service marketing, namely, marketing the goods and services of others; product and service marketing, namely, marketing the goods and services of others relating to blood for medical purposes, blood components, especially blood plasma, and also relating to hosting product platforms and service/communication platforms on the internet, especially relating to blood-products and information relating to blood-products and blood-donation;Patient support programs being personal support services for families of patients with life threatening disorders, namely, companionship, help with medical forms, emotional counseling and emotional support;Blood bank services, blood donation being blood bank services; providing health information relating to blood products and blood donation; providing patient support information being heath information;Hosting product platforms and service/communication platforms being software and websites on the internet for others, especially relating to blood-products and information relating to blood-products and blood-donation, as well as patient support information and patient support programs;

MYPANZYGA

MY PANZYGA;Marketing services; product and service marketing, namely, marketing the goods and services of others; product and service marketing, namely, marketing the goods and services of others relating to blood for medical purposes, blood components, especially blood plasma, and also relating to hosting product platforms and service/communication platforms on the internet, especially relating to blood-products and information relating to blood-products and blood-donation;Patient support programs being personal support services for families of patients with life threatening disorders, namely, companionship, help with medical forms, emotional counseling and emotional support;Blood bank services, blood donation being blood bank services; providing health information relating to blood-products and blood-donation; providing patient support information being health information;Hosting product platforms and service/communication platforms being software and websites on the internet for others, especially relating to blood-products and information relating to blood-products and blood-donation, as well as patient support information and patient support programs;

NUPREVIQ

NU PREVIQ;Medical testing of patients for determining individual risk of forming inhibitors during a hemophilia treatment with factor VIII;

NUVIQ

Pharmaceutical products, namely, blood plasma clotting factors, particularly recombinant factor VIII;

NUWIQ

Pharmaceutical products, namely blood coagulation factors, particularly recombinant factors VIII;

OCTACOL

medicaments; namely, blood preparations for spraying onto or into a patient's body, fibrin glue and components of fibrin glue;

OCTACOL

medicaments, namely blood preparations for spraying onto or into a patient's body, fibrin glue and components of fibrin glue;

OCTAGAM

medicaments, namely blood preparations for intravenous application derived from blood or plasma;

OCTAGAM

Pharmaceutical products, namely blood preparations for intravenous application;

OCTAGAM

Medicines in the nature of blood plasma derived products, namely, immunoglobulins to be injected;Color is not claimed as a feature of the mark.;

OCTAJET

Medical apparatus and instruments for reconstituting lyophilized fibrinogen powder; medical devices for transferring water to lyophilized fibrinogen powder to reconstitute the fibrinogen for preparation of fibrinogen solutions for injections and infusions;

OCTALIQUID

medicaments; namely, preparations for injection derived from blood plasma for the treatment of hemophilia;OCTA-LIQUID;

OCTANATE

Pharmaceutical products, namely, factor VIII preparations obtained from human blood plasma for prophylaxis and treatment of bleeding in patients with haemophilia A;

OCTANINE F

Pharmaceutical preparations, namely, blood coagulation factors from blood plasma;

OCTAPHARMA

Medical services, namely, medical services of a blood donation center;

OCTAPHARMA

Treatment of materials, namely, treatment of blood or blood plasma in pharmaceutical preparations, particularly of blood plasma preparations, plasma derivatives, coagulation factors, growth factors, proteins derived from plasma;The mark consists of the word otapharma.;Pharmaceutical preparations, particularly blood plasma preparations, plasma derivatives, coagulation factors, growth factors, proteins derived from plasma;Color is not claimed as a feature of the mark.;Medical services, particularly the medical services of a blood donation center;

OCTAPHARMA PLASMA

Pharmaceutical products, namely, blood plasma;PLASMA;

OCTAPLAS

The mark consists of the word OCTAPLAS.;Medicines, namely, blood plasma preparations;Color is not claimed as a feature of the mark.;